Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty.

Saved in:
Bibliographic Details
Title: Economic Evaluation of the Addition of Vancomycin to Cefazolin Prophylaxis in Patients Undergoing Arthroplasty.
Authors: Tran-Duy A; Health Economics and Simulation Modelling Unit, Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia. an.tran@unimelb.edu.au.; Methods and Implementation Support for Clinical and Health research (MISCH) Hub, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia. an.tran@unimelb.edu.au., Asbury S; Department of Infectious Diseases, Bayside Health, Melbourne, VIC, Australia.; Department of Infectious Diseases, School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia., Spelman T; Department of Health Services Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia.; Burnet Institute, Melbourne, VIC, Australia., Paterson DL; ADVANCE-ID, Saw Swee Hock School for Public Health, National University of Singapore, Singapore, Singapore.; Infectious Diseases Translational Research Programme, NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Buising KL; Royal Melbourne Hospital, Melbourne, VIC, Australia.; Department of Infectious Diseases, Doherty Institute, University of Melbourne, Melbourne, VIC, Australia., McDougall C; University of Queensland and Prince Charles Hospital, Brisbane, QLD, Australia., Solomon M; Prince of Wales Hospital, Randwick, Sydney, NSW, Australia.; Prince of Wales Private Hospital, Randwick, Sydney, NSW, Australia., Crawford R; Department of Orthopaedics, The Prince Charles Hospital, Metro North Hospital and Health Service, Brisbane, QLD, Australia.; Queensland University of Technology, Brisbane, QLD, Australia., Adie S; School of Clinical Medicine, St. George and Sutherland Clinical Campuses, UNSW Medicine & Health, UNSW Sydney, Sydney, Australia., Molnar R; St George & Sutherland Clinical Campuses, School of Clinical Medicine, University of New South Wales Medicine & Health, Sydney, Australia., Mulford J; Department of Orthopaedics, Launceston General Hospital, Tasmanian Health Service, Launceston, TAS, Australia., Harris-Brown T; Clinical Trials Centre, University of Queensland, Brisbane, QLD, Australia., Roney J; Department of Infectious Diseases, Bayside Health, Melbourne, VIC, Australia., de Steiger R; Department of Surgery, Epworth Healthcare, University of Melbourne, Melbourne, VIC, Australia., Peel TN; Department of Infectious Diseases, Bayside Health, Melbourne, VIC, Australia.; Department of Infectious Diseases, School of Translational Medicine, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
Corporate Authors: ASAP Trial Group
Source: PharmacoEconomics [Pharmacoeconomics] 2026 Jul; Vol. 44 (7), pp. 839-849. Date of Electronic Publication: 2026 Mar 13.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 9212404 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2027 (Electronic) Linking ISSN: 11707690 NLM ISO Abbreviation: Pharmacoeconomics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1179-2027
DOI:10.1007/s40273-026-01609-0